StockNews.com Begins Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)

Analysts at StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a report released on Sunday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Trading Down 25.5 %

NASDAQ:BLPH opened at $0.01 on Friday. Bellerophon Therapeutics has a 12-month low of $0.01 and a 12-month high of $0.02. The stock’s 50 day simple moving average is $0.02 and its 200-day simple moving average is $0.03. The firm has a market cap of $146,796.00, a P/E ratio of -0.01 and a beta of 0.74.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.